Boston Medical Center
- Type
- Teaching hospital
- Where
- EAST BOSTON, MA
- Medicare CCN
- 220031
- Received
- $5,070,701 in 469 records, 2021 ($629,092 general, $4,441,608 research)
- Source
- CMS Open Payments search ↗
On this site
- Business registration: Boston Medical Center Corporation Fuzzy (name and state)
- Business registration: BOSTON MEDICAL CENTER CORPORATION Fuzzy (name and state)
- Business registration: BOSTON MEDICAL CENTER CORPORATION Fuzzy (name and state)
- Business registration: BOSTON MEDICAL CENTER CORPORATION Fuzzy (name and state)
- Business registration: BOSTON MEDICAL CENTER CORPORATION Fuzzy (name and state)
- Nonprofit contractor: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Plan sponsor: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Federal award recipient: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Federal award recipient: BOSTON MEDICAL CENTER CORPORATION Fuzzy (name and state)
- Lobbying client: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Nonprofit: BOSTON MEDICAL CENTER CORPORATION Fuzzy (name and state)
- Patent assignee: BOSTON MEDICAL CENTER CORPORATION Fuzzy (name and state)
- Trademark owner: Boston Medical Center Corporation Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2021 | General payment | 75 | $629,092 |
| 2021 | Research payment | 394 | $4,441,608 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 394 | $4,441,608 |
| Grant | 7 | $333,896 |
| Charitable Contribution | 24 | $159,974 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 12 | $60,000 |
| Education | 27 | $55,692 |
| Royalty or License | 1 | $15,000 |
| Long term medical supply or device loan | 1 | $3,817 |
| Debt forgiveness | 3 | $711 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2021-12-31 | Merck Sharp & Dohme LLC | $198,568 | Research payment | In-kind items and services | Characterization of Systemic and Local Immune Responses to Chlamydia Antigens in Women to support Vaccine Antigen Select | 2021 | |
| 2021-12-31 | Gilead Sciences, Inc. | $70,583 | Grant | Cash or cash equivalent | 2021 | ||
| 2021-12-31 | Merck Sharp & Dohme LLC | $39,090 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as A | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $23,854 | Research payment | In-kind items and services | GARDASIL 9 Biological, VACCINE | An Open-Label Clinical Trial Evaluating the Immunogenicity of the 9-valent 2-dose Vaccination Regimen over 6 months Amon | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $20,831 | Research payment | In-kind items and services | IMPLANON Drug, WOMENS HEALTH | A Phase 3, Open-label, Multi-center, Single Arm Study to Assess Contraceptive Efficacy and Safety of the Etonogestrel MK | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $13,778 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as A | 2021 |
| 2021-12-31 | KARL STORZ Endoscopy-America | $13,059 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $6,408 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $3,638 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $3,016 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $2,994 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $2,876 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2021 | |
| 2021-12-31 | Merck Sharp & Dohme LLC | $2,779 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2021 |
| 2021-12-31 | KARL STORZ Endoscopy-America | $2,773 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2021 | |
| 2021-12-31 | Merck Sharp & Dohme LLC | $2,650 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-Blind Study of Pembrolizumab plus Ipilimumab vs Pembrolizumab plus Placebo in Previously U | 2021 |
| 2021-12-31 | KARL STORZ Endoscopy-America | $2,183 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $2,073 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $2,029 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $2,022 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $1,852 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $1,660 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $1,660 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2021 | |
| 2021-12-31 | AstraZeneca UK Limited | $1,652 | Research payment | In-kind items and services | SAPHNELO Biological, Inflammation and Autoimmunity | Safety and Efficacy of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Proliferative Lupus Ne | 2021 |
| 2021-12-31 | KARL STORZ Endoscopy-America | $1,547 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2021 | |
| 2021-12-31 | Roche Diagnostics Operations, Inc. | $1,527 | Research payment | Cash or cash equivalent | cobas c 311 Device, Core Lab | CIMRD001469 | 2021 |
| 2021-12-31 | KARL STORZ Endoscopy-America | $1,411 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $872 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $872 | Education | In-kind items and services | Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $814 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $490 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2021 | |
| 2021-12-31 | ABBVIE INC. | $442 | Research payment | In-kind items and services | A Randomized, Double-Blind, Placebo-Controlled Proof of Concept Study to Assess the Safety and Efficacy of Elezanumab in | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $281 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $189 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $125 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $57 | Education | In-kind items and services | Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $57 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $24 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2021 | |
| 2021-12-29 | PFIZER INC. | $8,919 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2021 |
| 2021-12-29 | PFIZER INC. | $3,011 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2021 |
| 2021-12-28 | PFIZER INC. | $20,579 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2021 |
| 2021-12-28 | Intercept Pharmaceuticals, Inc. | $1,365 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | 2021 |
| 2021-12-28 | Novo Nordisk AS | $50 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2021 |
| 2021-12-24 | PFIZER INC. | $25,234 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2021 |
| 2021-12-23 | Merck Sharp & Dohme LLC | $43,274 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as A | 2021 |
| 2021-12-23 | Alexion Pharmaceuticals, Inc. | $12,490 | Research payment | Cash or cash equivalent | A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Rav | 2021 | |
| 2021-12-22 | PFIZER INC. | $6,420 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT | 2021 |
| 2021-12-22 | Novo Nordisk AS | $2,308 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4352 | 2021 |
| 2021-12-22 | PFIZER INC. | $1,003 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2021 |
| 2021-12-21 | Akcea Therapeutics, Inc. | $6,518 | Research payment | Cash or cash equivalent | TEGSEDI Drug, NEUROLOGY | IST-2019-0601 | 2021 |
| 2021-12-15 | Indivior Inc. | $5,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SUBLOCADE Drug, OUD | 2021 | |
| 2021-12-15 | Indivior Inc. | $5,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SUBLOCADE Drug, OUD | 2021 | |
| 2021-12-15 | Bio-Rad Laboratories, Inc. | $591 | Debt forgiveness | Cash or cash equivalent | Liquichek Device, Controls | 2021 | |
| 2021-12-13 | Janssen Research & Development, LLC | $18,730 | Research payment | Cash or cash equivalent | An Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation E | 2021 | |
| 2021-12-13 | Janssen Research & Development, LLC | $2,920 | Research payment | Cash or cash equivalent | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide Bortezo | 2021 | |
| 2021-12-09 | Takeda Pharmaceuticals U.S.A., Inc. | $1,911 | Research payment | Cash or cash equivalent | ENTYVIO (VEDOLIZUMAB) LONG-TERM SAFETY STUDY: AN INTERNATIONAL OBSERVATIONAL PROSPECTIVE COHORT STUDY COMPARING VEDOLIZU | 2021 | |
| 2021-12-09 | Novo Nordisk AS | $25 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2021 |
| 2021-12-09 | Novo Nordisk AS | $9 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2021 |
| 2021-12-08 | VERTEX PHARMACEUTICALS INCORPORATED | $50,000 | Grant | Cash or cash equivalent | 2021 | ||
| 2021-12-08 | PFIZER INC. | $6,998 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2021 |
| 2021-12-07 | PFIZER INC. | $33,974 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2021 |
| 2021-12-07 | PFIZER INC. | $4,029 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT | 2021 |
| 2021-12-07 | PFIZER INC. | $3,963 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIA | 2021 | |
| 2021-12-07 | Hoffmann-La Roche Limited | $1,890 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | SAFETY EFFICACY OF A COMBINATION OF REMDESIVIR TOCILIZUMAB IN SEVERE COVID 19 PNEUMONIA | 2021 |
| 2021-12-07 | Rigel Pharmaceuticals, Inc. | $1,625 | Research payment | Cash or cash equivalent | Tavalisse Drug, Hematology | O-FOSTA-901 | 2021 |
| 2021-12-06 | Boston Scientific Corporation | $827 | Research payment | Cash or cash equivalent | Resonate Device, Tachy | PRECISION EVENT MONITORING OF PATIENTS WITH HF USING HEARTLO | 2021 |
| 2021-12-03 | G1 Therapeutics, Inc. | $22,176 | Research payment | Cash or cash equivalent | Cosela Drug, HEMATOLOGY AND ONCOLOGY | G1T28-207 | 2021 |
| 2021-12-02 | PFIZER INC. | $11,823 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2021 |
| 2021-12-02 | Novo Nordisk AS | $25 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2021 |
| 2021-12-02 | Novo Nordisk AS | $9 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2021 |
| 2021-12-01 | PFIZER INC. | $285,600 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2021 |
| 2021-12-01 | Novo Nordisk AS | $5,277 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4352 | 2021 |
| 2021-12-01 | Laminate Medical Technologies inc. | $5,167 | Research payment | Cash or cash equivalent | VasQ External Support Device, B | A Multi-center Prospective Study to Evaluate the Safety and Effectiveness of the VasQ External Support for Arteriovenous | 2021 |
| 2021-12-01 | Hoffmann-La Roche Limited | $764 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | SAFETY EFFICACY OF A COMBINATION OF REMDESIVIR TOCILIZUMAB IN SEVERE COVID 19 PNEUMONIA | 2021 |
| 2021-12-01 | Novo Nordisk AS | $375 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4352 | 2021 |
| 2021-11-25 | PFIZER INC. | $17,441 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2021 |
| 2021-11-24 | PFIZER INC. | $4,934 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2021 |
| 2021-11-23 | PFIZER INC. | $22,584 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT | 2021 |
| 2021-11-23 | Abbott Laboratories | $15,742 | Research payment | In-kind items and services | Architect i2000SR Analyser System Device, Core Diagnostics | Performance Evaluation of Architect SARS-CoV-2 IgG & IgM vs Alinity SARS-CoV-2 IgG & IgM | 2021 |
| 2021-11-23 | PFIZER INC. | $13,860 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIA | 2021 | |
| 2021-11-18 | Hoffmann-La Roche Limited | $2,500 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | SAFETY EFFICACY OF A COMBINATION OF REMDESIVIR TOCILIZUMAB IN SEVERE COVID 19 PNEUMONIA | 2021 |
| 2021-11-18 | PFIZER INC. | $1,388 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2021 |
| 2021-11-18 | Hoffmann-La Roche Limited | $1,300 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | SAFETY EFFICACY OF A COMBINATION OF REMDESIVIR TOCILIZUMAB IN SEVERE COVID 19 PNEUMONIA | 2021 |
| 2021-11-18 | Hoffmann-La Roche Limited | $1,300 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | SAFETY EFFICACY OF A COMBINATION OF REMDESIVIR TOCILIZUMAB IN SEVERE COVID 19 PNEUMONIA | 2021 |
| 2021-11-18 | Medline Industries LP | $629 | Research payment | In-kind items and services | DRESSING, GEL FIBER, OPTICELL AG Device, Dermatology/Wound Care | Opticell and Aquacel study: A comparative evaluation of a marine polysaccharide dressing and a carboxymethylcellulose dr | 2021 |
| 2021-11-18 | Hoffmann-La Roche Limited | $487 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | SAFETY EFFICACY OF A COMBINATION OF REMDESIVIR TOCILIZUMAB IN SEVERE COVID 19 PNEUMONIA | 2021 |
| 2021-11-17 | Organon Llc | $2,358 | Research payment | Cash or cash equivalent | IMPLANON Drug, CONTRACEPTIVES | A Phase 3, Open-label, Multi-center, Single Arm Study to Assess Contraceptive Efficacy and Safety of the Etonogestrel MK | 2021 |
| 2021-11-16 | Becton, Dickinson and Company | $370 | Charitable Contribution | In-kind items and services | 2021 | ||
| 2021-11-16 | Becton, Dickinson and Company | $62 | Charitable Contribution | In-kind items and services | 2021 | ||
| 2021-11-16 | Becton, Dickinson and Company | $55 | Charitable Contribution | In-kind items and services | 2021 | ||
| 2021-11-16 | Becton, Dickinson and Company | $47 | Charitable Contribution | In-kind items and services | 2021 | ||
| 2021-11-15 | Becton, Dickinson and Company | $202 | Charitable Contribution | In-kind items and services | 2021 | ||
| 2021-11-12 | Neurocrine BioSciences, Inc. | $1,300 | Research payment | Cash or cash equivalent | OPEN-LABEL ROLLOVER STUDY FOR CONTINUING VALBENAZINE ADMINISTRATION FOR THE TREATMENT OF CHOREA ASSOCIATED WITH HUNTINGT | 2021 | |
| 2021-11-12 | Neurocrine BioSciences, Inc. | $1,300 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF VALBEN | 2021 | |
| 2021-11-11 | Becton, Dickinson and Company | $11,047 | Charitable Contribution | In-kind items and services | 2021 | ||
| 2021-11-11 | Becton, Dickinson and Company | $1,439 | Charitable Contribution | In-kind items and services | 2021 | ||
| 2021-11-11 | Becton, Dickinson and Company | $191 | Charitable Contribution | In-kind items and services | 2021 | ||
| 2021-11-11 | Becton, Dickinson and Company | $125 | Charitable Contribution | In-kind items and services | 2021 | ||
| 2021-11-10 | Takeda Pharmaceuticals U.S.A., Inc. | $9,684 | Research payment | Cash or cash equivalent | TEDUGLUTIDE FOR TREATMENT OF SHORT BOWEL SYNDROME IN REAL WORLD SETTINGS: CENTER-BASED STUDY IN THE US AND EU | 2021 | |
| 2021-11-10 | PFIZER INC. | $4,571 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2021 |
| 2021-11-10 | PFIZER INC. | $1,418 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2021 |
| 2021-11-10 | Becton, Dickinson and Company | $55 | Charitable Contribution | In-kind items and services | 2021 | ||
| 2021-11-10 | Becton, Dickinson and Company | $47 | Charitable Contribution | In-kind items and services | 2021 | ||
| 2021-11-09 | Becton, Dickinson and Company | $45 | Charitable Contribution | In-kind items and services | 2021 | ||
| 2021-11-09 | Becton, Dickinson and Company | $33 | Charitable Contribution | In-kind items and services | 2021 | ||
| 2021-11-09 | Becton, Dickinson and Company | $33 | Charitable Contribution | In-kind items and services | 2021 | ||
| 2021-11-08 | Organon Llc | $16,763 | Research payment | Cash or cash equivalent | IMPLANON Drug, CONTRACEPTIVES | 8415-8415-060-PN060-Extended Duration Study (Celanese + 2 years)-Contraception-SC-imp-Supplemental Registration-USA-LD-B | 2021 |
| 2021-11-08 | Becton, Dickinson and Company | $258 | Charitable Contribution | In-kind items and services | 2021 | ||
| 2021-11-08 | Becton, Dickinson and Company | $242 | Charitable Contribution | In-kind items and services | 2021 | ||
| 2021-11-08 | Becton, Dickinson and Company | $201 | Charitable Contribution | In-kind items and services | 2021 | ||
| 2021-11-08 | Becton, Dickinson and Company | $176 | Charitable Contribution | In-kind items and services | 2021 | ||
| 2021-11-08 | Becton, Dickinson and Company | $121 | Charitable Contribution | In-kind items and services | 2021 | ||
| 2021-11-08 | Becton, Dickinson and Company | $95 | Charitable Contribution | In-kind items and services | 2021 | ||
| 2021-11-08 | Becton, Dickinson and Company | $55 | Charitable Contribution | In-kind items and services | 2021 | ||
| 2021-11-08 | Organon Llc | $20 | Research payment | Cash or cash equivalent | IMPLANON Drug, CONTRACEPTIVES | A Phase 3, Open-label, Multi-center, Single Arm Study to Assess Contraceptive Efficacy and Safety of the Etonogestrel MK | 2021 |
| 2021-11-05 | PFIZER INC. | $9,369 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIA | 2021 | |
| 2021-11-05 | PFIZER INC. | $634 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY IN | 2021 |
| 2021-11-04 | Novo Nordisk AS | $23 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2021 |
| 2021-11-04 | Novo Nordisk AS | $2 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2021 |
| 2021-11-03 | Alexion Pharmaceuticals, Inc. | $489 | Research payment | Cash or cash equivalent | A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Rav | 2021 | |
| 2021-11-01 | Boston Scientific Corporation | $28,887 | Research payment | Cash or cash equivalent | Resonate Device, Tachy | PRECISION EVENT MONITORING OF PATIENTS WITH HF USING HEARTLO | 2021 |
| 2021-10-30 | PFIZER INC. | $3,944 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2021 |
| 2021-10-29 | Janssen Research & Development, LLC | $476 | Research payment | Cash or cash equivalent | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide Bortezo | 2021 | |
| 2021-10-28 | ABBVIE INC. | $1,879 | Research payment | Cash or cash equivalent | An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in P | 2021 | |
| 2021-10-27 | COLOPLAST CORP | $120,000 | Charitable Contribution | Cash or cash equivalent | Titan Device, Men's Health | 2021 | |
| 2021-10-27 | Novo Nordisk AS | $6,758 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4352 | 2021 |
| 2021-10-27 | Novo Nordisk AS | $3,000 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4352 | 2021 |
| 2021-10-27 | PFIZER INC. | $1,388 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2021 |
| 2021-10-26 | Takeda Pharmaceuticals U.S.A., Inc. | $961 | Research payment | Cash or cash equivalent | GATTEX Drug, INTERNAL MEDICINE | A PROSPECTIVE, MULTI-CENTER REGISTRY FOR PATIENTS WITH SHORT BOWEL SYNDROME | 2021 |
| 2021-10-21 | Hoffmann-La Roche Limited | $52,826 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | SAFETY EFFICACY OF A COMBINATION OF REMDESIVIR TOCILIZUMAB IN SEVERE COVID 19 PNEUMONIA | 2021 |
| 2021-10-20 | Medline Industries LP | $1,366 | Research payment | Cash or cash equivalent | DRESSING, GEL FIBER, OPTICELL AG Device, Dermatology/Wound Care | Opticell and Aquacel study: A comparative evaluation of a marine polysaccharide dressing and a carboxymethylcellulose dr | 2021 |
| 2021-10-20 | Organon Llc | $491 | Research payment | Cash or cash equivalent | IMPLANON Drug, CONTRACEPTIVES | A Phase 3, Open-label, Multi-center, Single Arm Study to Assess Contraceptive Efficacy and Safety of the Etonogestrel MK | 2021 |
| 2021-10-16 | PFIZER INC. | $2,715 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2021 |
| 2021-10-16 | PFIZER INC. | $1,269 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY IN | 2021 |
| 2021-10-13 | Indivior Inc. | $5,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SUBLOCADE Drug, OUD | 2021 | |
| 2021-10-13 | Indivior Inc. | $5,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SUBLOCADE Drug, OUD | 2021 | |
| 2021-10-11 | C. R. Bard, Inc. & Subsidiaries | $62,800 | Research payment | Cash or cash equivalent | Arctic Sun 5000 Device, Medical Systems | INTREPID BMD1111 | 2021 |
| 2021-10-09 | PFIZER INC. | $10,023 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2021 |
| 2021-10-09 | PFIZER INC. | $53 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIA | 2021 | |
| 2021-10-08 | PFIZER INC. | $8,033 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIA | 2021 | |
| 2021-10-08 | PFIZER INC. | $3,292 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT | 2021 |
| 2021-10-05 | PFIZER INC. | $6,170 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2021 |
| 2021-10-04 | Bayer Healthcare Pharmaceuticals Inc. | $435 | Research payment | Cash or cash equivalent | Mirena Drug, Women's Health | BAY86-5028 Mirena extension contraception | 2021 |
| 2021-10-01 | Merck Sharp & Dohme LLC | $98,893 | Research payment | Cash or cash equivalent | STEGLATRO Drug, ENDOCRINOLOGY | STUDY NAMEEffects of SGLT2 inhibition on cardiac mitochondrial function, energetics and remodeling in non-diabetic mice | 2021 |
| 2021-09-29 | PFIZER INC. | $9,100 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2021 |
| 2021-09-29 | Johnson & Johnson Health Care Systems Inc. | $120 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-09-28 | PFIZER INC. | $285,507 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2021 |
| 2021-09-28 | Merck Sharp & Dohme LLC | $149,226 | Research payment | Cash or cash equivalent | ISENTRESS Drug, INFECTIOUS DISEASE | Intensified antiretroviral therapy with raltegravir in acute HIV infection to limit establishment of the viral reservoir | 2021 |
| 2021-09-28 | Novo Nordisk AS | $23 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2021 |
| 2021-09-28 | Novo Nordisk AS | $2 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2021 |
| 2021-09-25 | PFIZER INC. | $25,430 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2021 |
| 2021-09-24 | Novo Nordisk AS | $3,438 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4352 | 2021 |
| 2021-09-24 | Novo Nordisk AS | $375 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4352 | 2021 |
| 2021-09-23 | ABBVIE INC. | $2,171 | Research payment | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | A Phase 3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared with Pomalidomide and Dexa | 2021 |
| 2021-09-22 | Rigel Pharmaceuticals, Inc. | $3,762 | Research payment | Cash or cash equivalent | Tavalisse Drug, Hematology | O-FOSTA-901 | 2021 |
| 2021-09-22 | Rigel Pharmaceuticals, Inc. | $1,625 | Research payment | Cash or cash equivalent | Tavalisse Drug, Hematology | O-FOSTA-901 | 2021 |
| 2021-09-22 | Rigel Pharmaceuticals, Inc. | $1,625 | Research payment | Cash or cash equivalent | Tavalisse Drug, Hematology | O-FOSTA-901 | 2021 |
| 2021-09-22 | Rigel Pharmaceuticals, Inc. | $1,625 | Research payment | Cash or cash equivalent | Tavalisse Drug, Hematology | O-FOSTA-901 | 2021 |
| 2021-09-22 | Rigel Pharmaceuticals, Inc. | $1,625 | Research payment | Cash or cash equivalent | Tavalisse Drug, Hematology | O-FOSTA-901 | 2021 |
| 2021-09-22 | PFIZER INC. | $1,572 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY IN | 2021 |
| 2021-09-22 | PFIZER INC. | $944 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIA | 2021 | |
| 2021-09-21 | PFIZER INC. | $6,440 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2021 |
| 2021-09-21 | ABBVIE INC. | $2,427 | Research payment | Cash or cash equivalent | An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in P | 2021 | |
| 2021-09-15 | PFIZER INC. | $9,504 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT | 2021 |
| 2021-09-14 | PFIZER INC. | $8,674 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2021 |
| 2021-09-08 | PFIZER INC. | $8,596 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2021 |
| 2021-09-04 | PFIZER INC. | $6,948 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIA | 2021 | |
| 2021-09-04 | PFIZER INC. | $2,510 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY IN | 2021 |
| 2021-09-03 | Novo Nordisk AS | $23 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2021 |
| 2021-09-03 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2021 |
| 2021-09-03 | Johnson & Johnson Health Care Systems Inc. | $0 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-09-02 | Celgene Corporation | $4,986 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Open-Label Extension Trial | 2021 | |
| 2021-09-01 | Novo Nordisk AS | $69 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2021 |
| 2021-08-31 | PFIZER INC. | $4,551 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2021 |
| 2021-08-31 | Becton, Dickinson and Company | $64 | Charitable Contribution | In-kind items and services | 2021 | ||
| 2021-08-30 | Janssen Research & Development, LLC | $635 | Research payment | Cash or cash equivalent | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide Bortezo | 2021 | |
| 2021-08-27 | Abbott Laboratories | $31,484 | Research payment | In-kind items and services | Architect i2000SR Analyser System Device, Core Diagnostics | Performance Evaluation of Architect SARS-CoV-2 IgG & IgM vs Alinity SARS-CoV-2 IgG & IgM | 2021 |
| 2021-08-27 | PFIZER INC. | $27,271 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT | 2021 |
| 2021-08-26 | Janssen Research & Development, LLC | $765 | Research payment | Cash or cash equivalent | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide Bortezo | 2021 | |
| 2021-08-25 | Novo Nordisk AS | $3,374 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4352 | 2021 |
| 2021-08-25 | G1 Therapeutics, Inc. | $2,609 | Research payment | Cash or cash equivalent | Cosela Drug, HEMATOLOGY AND ONCOLOGY | G1T28-207 | 2021 |
| 2021-08-25 | Alexion Pharmaceuticals, Inc. | $1,793 | Research payment | Cash or cash equivalent | A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Rav | 2021 | |
| 2021-08-24 | PFIZER INC. | $1,875 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY IN | 2021 |
| 2021-08-24 | PFIZER INC. | $709 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2021 |
| 2021-08-21 | PFIZER INC. | $47,304 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT | 2021 |
| 2021-08-21 | PFIZER INC. | $5,675 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIA | 2021 | |
| 2021-08-20 | Novo Nordisk AS | $56 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2021 |
| 2021-08-20 | Novo Nordisk AS | $56 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2021 |
| 2021-08-20 | Novo Nordisk AS | $56 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2021 |
| 2021-08-20 | Novo Nordisk AS | $56 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2021 |
| 2021-08-20 | Novo Nordisk AS | $56 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2021 |
| 2021-08-20 | Novo Nordisk AS | $56 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2021 |
| 2021-08-20 | Novo Nordisk AS | $56 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2021 |
| 2021-08-20 | Novo Nordisk AS | $56 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2021 |
| 2021-08-20 | Novo Nordisk AS | $56 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2021 |
| 2021-08-20 | Novo Nordisk AS | $56 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2021 |
| 2021-08-20 | Novo Nordisk AS | $56 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2021 |
| 2021-08-20 | Novo Nordisk AS | $56 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2021 |
| 2021-08-20 | Novo Nordisk AS | $56 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2021 |
| 2021-08-20 | Novo Nordisk AS | $56 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2021 |
| 2021-08-20 | Novo Nordisk AS | $56 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2021 |
The latest 200 records of 469.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
In Massachusetts; placed by its state only.
| Measure | State Massachusetts |
|---|---|
| Population B01003 | 7,044,056 |
| Population, 2020 census P1 | 7,029,917 |
| Median age B01002 | 40.0 |
| Under 18 B01001 | 19.4% |
| 65 and over B01001 | 17.9% |
| Households B11001 | 2,785,042 |
| Foreign born B05002 | 18.0% |
| Median household income B19013 | $103,960 |
| Median family income B19113 | $131,675 |
| Per capita income B19301 | $57,897 |
| Poverty rate B17001 | 10.0% |
| Unemployment rate B23025 | 5.2% |
| Civilian labor force B23025 | 3,911,446 |
| Mean commute (minutes) B08013 | 29.1 |
| Bachelor's degree or higher B15003 | 47.3% |
| Housing units B25001 | 3,030,406 |
| Owner-occupied B25003 | 62.5% |
| Renters B25003 | 37.5% |
| Median home value B25077 | $562,100 |
| Median gross rent B25064 | $1,762 |
| White, not Hispanic B03002 | 66.6% |
| Black B03002 | 6.4% |
| Hispanic or Latino B03002 | 13.3% |
| Asian B03002 | 7.3% |
| American Indian and Alaska Native B03002 | 0.1% |
Economy now FRED unemployment 4.3% in Sep 2026 (4.6% a year earlier); per capita personal income $98,700 in 2025, up 27% in five years (+2.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Massachusetts.
Comments